Clowse, M. E. B., Wolf, D. C., Förger, F., Cush, J. J., Golembesky, A., Shaughnessy, L., … Mahadevan, U. (2014). OP0067 Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance. In Annals of the Rheumatic Diseases (Vol. 73, pp. 85–86). Elsevier BV. https://doi.org/10.1136/annrheumdis-2014-eular.1996

Clowse, M. E. B., D. C. Wolf, F. Förger, J. J. Cush, A. Golembesky, L. Shaughnessy, D. De Cuyper, K. Luijtens, S. Abbas, and U. Mahadevan. “OP0067 Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance.” In Annals of the Rheumatic Diseases, 73:85–86. Elsevier BV, 2014. https://doi.org/10.1136/annrheumdis-2014-eular.1996.

Clowse MEB, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, et al. OP0067 Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance. In: Annals of the Rheumatic Diseases. Elsevier BV; 2014. p. 85–6.

Clowse, M. E. B., et al. “OP0067 Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance.” Annals of the Rheumatic Diseases, vol. 73, Elsevier BV, 2014, pp. 85–86. Crossref, doi:10.1136/annrheumdis-2014-eular.1996.

Clowse MEB, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Luijtens K, Abbas S, Mahadevan U. OP0067 Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance. Annals of the Rheumatic Diseases. Elsevier BV; 2014. p. 85–86.